Sagimet Biosciences

Developing a portfolio of novel therapeutics called fatty acid synthase (FASN) inhibitors.

About

Founded

2006

Headquarters

San Mateo, California

Industry

Healthcare, Biotech

Company Description

We are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors to treat important diseases such as non-alcoholic steatohepatitis (NASH), acne and various cancers.

Quick Links

Website Jobs

Funding

Total Raised

$293.7 million

Valuation

Undisclosed

Significant Investors

Kleiner Perkins, Altium Capital, HM Capital, Invus, PFM Health Sciences, New Enterprise Associates, Rock Springs Capital, Ascletis

Company Traction

In June 2023, Sagimet Biosciences presented a positive Phase 2B of FASCINATE-2 clinical trial for denifanstat.

Leadership Team

Dave Happel: CEO & President at Sagimet Biosciences. Former CEO & President at Cognoa.

Dennis Hom: CFO and Head of Corporate Development at Sagimet Biosciences. Former VP of Finance and Corporate Development at Achaogen.

Eduardo Martins: Chief Medical Officer at Sagimet Biosciences. Former VP of Clinical Development at AbbVie.

Tony Rimac: COO at Sagimet Biosciences. Former CFO at Cognoa.

Marie O'Farrell: SVP of Research and Development at Sagimet Biosciences. Former Senior Director, Translational Sciences at 3-V Biosciences.

Press

MarketWatch (June 23, 2023): Sagimet Biosciences gives going public a second chance under new CEO

FinSMEs (February 12, 2021): Sagimet Biosciences Raises $80M in Crossover Financing